Akari Therapeutics PLC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Akari Therapeutics registers up to 2.5 million ADSs for potential resale by White Lion Capital under a $25 million purchase agreement.
NASDAQ
Akari Therapeutics, PLC has filed a registration statement for a best-efforts offering of ADSs and warrants to raise approximately $7.5 million for research and development.
NASDAQ
Akari Therapeutics, an oncology company, is shifting its focus to next-generation antibody-drug conjugates (ADCs) following a recent merger, but faces significant financial challenges and a Nasdaq delisting threat.
NASDAQ
Akari Therapeutics filed an S-1 registration statement for the resale of 6.375 million ADSs by selling shareholders, stemming from recent warrant issuances.
NASDAQ
Akari Therapeutics has entered into an agreement with White Lion Capital for an equity line of up to $25 million, providing discretionary capital access over the next three years.